Mirum Pharmaceuticals ( (MIRM) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Mirum Pharmaceuticals’ shares came under pressure as investors weighed the limited commercial impact of a new product update from Health Canada. The regulator has authorized Livmarli tablets to treat cholestatic pruritus in Alagille syndrome patients who weigh at least 22 kg and can swallow pills. While this new tablet form adds convenience and dosing flexibility alongside the existing oral solution—especially as patients grow older—the news does not dramatically expand the drug’s addressable market, tempering market enthusiasm and contributing to the stock’s slide.
More about Mirum Pharmaceuticals
YTD Price Performance: 31.61%
Average Trading Volume: 766,494
Technical Sentiment Signal: Buy
Current Market Cap: $5.37B
For further insights into MIRM stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.